Edition:
United Kingdom

Dechra Pharmaceuticals PLC (DPH.L)

DPH.L on London Stock Exchange

2,862.00GBp
10:22am BST
Change (% chg)

-28.00 (-0.97%)
Prev Close
2,890.00
Open
2,882.00
Day's High
2,888.00
Day's Low
2,862.00
Volume
20,577
Avg. Vol
182,378
52-wk High
3,180.48
52-wk Low
1,992.00

Latest Key Developments (Source: Significant Developments)

Dechra Says HY Reported Rev Rose About 17% At CER
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Dechra Pharmaceuticals PLC ::TRADING UPDATE & NOTICE OF RESULTS.TRADING IN YEAR WAS STRONG AND IN LINE WITH MANAGEMENT EXPECTATIONS.REPORTED GROUP REVENUE FOR PERIOD INCREASED BY C.17% AT CONSTANT EXCHANGE RATE (CER).FY EUROPEAN PHARMACEUTICALS REVENUE GROWTH WAS C.18% AT CER (AER C.17%).FY NORTH AMERICA PHARMACEUTICALS REVENUE GROWTH WAS C.15% AT CER (AER C.20%).  Full Article

Dechra Pharmaceuticals Buys Further 15% Issued Share Capital Of Medical Ethics
Friday, 5 Jul 2019 

July 5 (Reuters) - Dechra Pharmaceuticals PLC ::INCREASED INVESTMENT IN MEDICAL ETHICS.ACQUIRED A FURTHER 15.0% OF ISSUED SHARE CAPITAL OF MEDICAL ETHICS PTY LTD.PROPOSED DEAL FOR TOTAL CONSIDERATION OF C.AUD$13.5 MILLION.FOLLOWING ACQUISITION, DECHRA WILL HOLD 48.0% OF ISSUED SHARE CAPITAL OF MEDICAL ETHICS.  Full Article

Dechra Pharmaceuticals Plc's CFO Richard Cotton To Leave
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Dechra Pharmaceuticals PLC ::RICHARD COTTON, CHIEF FINANCIAL OFFICER, HAS INFORMED BOARD OF HIS DECISION TO LEAVE COMPANY IMMEDIATELY FOR PERSONAL REASONS.SEARCH PROCESS FOR CFO REPLACEMENT HAS COMMENCED AND A FURTHER UPDATE ON THIS WILL BE MADE IN DUE COURSE.PAUL SANDLAND, DVP EU FINANCE DIRECTOR, WILL ASSUME ROLE OF ACTING CHIEF FINANCIAL OFFICER.TRADING ACROSS GROUP HAS CONTINUED TO WITNESS GROWTH AND IS IN LINE WITH MANAGEMENT EXPECTATIONS.  Full Article

Despite Brexit Uncertainty, Dechra Pharma Remains Confident For Financial Year Outlook
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Dechra Pharmaceuticals PLC ::DECHRA PHARM PLC - HALF-YEARLY FINANCIAL REPORT 2019.DECHRA PHARMACEUTICALS PLC - HY REVENUE 231.4 MILLION STG VERSUS 194.1 MILLION STG REPORTED A YEAR EARLIER.DECHRA PHARMACEUTICALS PLC - HY UNDERLYING OPERATING PROFIT 60.8 MILLION STG VERSUS 47.4 MILLION STG REPORTED A YEAR EARLIER.DECHRA PHARMACEUTICALS PLC - HY REPORTED OPERATING PROFIT 17.0 MILLION STG VERSUS 26.3 MILLION STG REPORTED A YEAR EARLIER.DECHRA PHARMACEUTICALS PLC - INTERIM DIVIDEND INCREASED BY 29.6% TO 9.5 PENCE.DECHRA PHARMACEUTICALS PLC - TRADING IN PERIOD WAS STRONG AND IN LINE WITH MANAGEMENT EXPECTATIONS.DECHRA PHARMACEUTICALS PLC - TRADING ACROSS GROUP HAS COMMENCED WELL IN SECOND HALF, WITH PARTICULARLY STRONG GROWTH CONTINUING IN USA.DECHRA PHARMACEUTICALS PLC - MATERIAL SYNERGIES FROM AST FARMA AND LE VET ACQUISITION WILL INCREASE IN SECOND HALF.DECHRA PHARMACEUTICALS PLC - INITIAL INDICATIONS ARE THAT RECENT ACQUISITION, VENCO, IS PERFORMING TO EXPECTATIONS.DECHRA PHARMACEUTICALS PLC - DESPITE UNCERTAINTY SURROUNDING BREXIT, WE REMAIN CONFIDENT IN OUTLOOK FOR REMAINDER OF FINANCIAL YEAR.  Full Article

Dechra Says It Is Implementing Hard Brexit Mitigation Plan
Monday, 3 Sep 2018 

Sept 3 (Reuters) - Dechra Pharmaceuticals PLC ::FY REVENUE GROWTH OF 13.9% TO £407.1 MILLION.FULL YEAR DIVIDEND OF 25.50 PENCE.FY UNDERLYING OPERATING PROFIT GROWTH OF 24.0% TO £99.2 MILLION.NEW FINANCIAL YEAR HAS STARTED WELL AND IN LINE WITH MANAGEMENT EXPECTATIONS.PROPOSING A FINAL DIVIDEND OF 18.17 PENCE PER SHARE.ENGAGED IN CONTINGENCY PLANNING AND ARE IMPLEMENTING A HARD BREXIT MITIGATION PLAN.EXPECT FINANCIAL IMPACT OF HARD BREXIT MITIGATION PLAN TO BE IMMATERIAL.  Full Article

Dechra Says ‍Trading In Line With Management Expectations
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Dechra Pharmaceuticals Plc ::‍TRADING IN PERIOD WAS STRONG AND IN LINE WITH MANAGEMENT EXPECTATIONS​.‍REPORTED GROUP REVENUE FOR PERIOD INCREASED BY C.10.5% AT CONSTANT EXCHANGE RATE (CER) (C.11.5% AT ACTUAL EXCHANGE RATE (AER))​.  Full Article

Dechra Pharmaceuticals ‍Q1 performance in line with management expectations
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Dechra Pharmaceuticals Plc ::DECHRA PHARMACEUTICALS - ‍ PERFORMANCE IN Q1 OF FINANCIAL YEAR WAS IN LINE WITH MANAGEMENT EXPECTATIONS, WITH CONTINUED GROWTH ACROSS ALL OF ITS MARKETS​.  Full Article

Dechra Pharmaceuticals says full-year revenue up at 359.3 mln stg
Monday, 4 Sep 2017 

Sept 4 (Reuters) - Dechra Pharmaceuticals Plc ::Preliminary results announcement -year end 30.6.17.Fy revenue growth of 28.3% at constant exchange rates (cer).Fy underlying diluted eps growth of 35.1%; increase in full year dividend to 21.44 pence.Current trading is in line with board expectations and we anticipate delivering our strategic objectives in new financial year.In year, dechra delivered consolidated revenue of £359.3 million, representing an increase of 28.3% on prior year.Consolidated underlying operating profit of £81.3 million, represents a 36.9% increase on prior year.Underlying ebit margin increased by 140bps to 22.6%.  Full Article

Ex-divs to take 21.7 points off FTSE 100 on March 7

LONDON, March 4 The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the latest dividend payout. According to Reuters calculations at current market prices, the effect of the resulting adjustment to prices by market-makers would take 21.7 points off the index. COMPANY (RIC) DIVIDEND STOCK OPTION IMPACT (pence) B